Martin Stern

Martin Stern has a strong background in the medical field with experience in clinical development, translational medicine, immunotherapy, hematology, and oncology.

- Martin is currently serving as the SVP Clinical Development at Numab Therapeutics AG, starting in September 2023.

- Prior to this, they held the role of Chief Medical Officer at Affivant from November 2022 to August 2023.

- Martin also worked at Roche as a Translational Medicine Leader from June 2014 to October 2022.

- In addition, they served as a Research Group Leader in Immunotherapy and a Professor at the University of Basel from October 2010 to October 2015.

- Before joining the University of Basel, Martin was a Consultant in Hematology at Universitätsspital Basel from July 2007 to May 2014.

- Martin conducted post-doctoral research in Experimental Hematology at the University of Perugia from July 2005 to June 2007.

- Martin started their medical career in Internal Medicine, Oncology, and Hematology at University Hospital Basel in January 2001, where they worked until June 2005.

Martin Stern attended the University of Basel from 1994 to 2000, where they obtained a Doctor of Medicine (MD) degree.